Cargando…
Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug Delivery
The current treatment for the acquired retinal vasculopathies involves lifelong repeated intravitreal injections of either anti-vascular endothelial growth factor (VEGF) therapy or modulation of inflammation with steroids. Consequently, any treatment modification that decreases this treatment burden...
Autores principales: | Dandamudi, Madhuri, McLoughlin, Peter, Behl, Gautam, Rani, Sweta, Coffey, Lee, Chauhan, Anuj, Kent, David, Fitzhenry, Laurence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541202/ https://www.ncbi.nlm.nih.gov/pubmed/34683883 http://dx.doi.org/10.3390/pharmaceutics13101590 |
Ejemplares similares
-
Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease
por: Kumari, Sangeeta, et al.
Publicado: (2021) -
Development of Triamcinolone Acetonide Nanocrystals for Ocular Administration
por: Formica, María Lina, et al.
Publicado: (2023) -
Hyaluronic Acid: Its Versatile Use in Ocular Drug Delivery with a Specific Focus on Hyaluronic Acid-Based Polyelectrolyte Complexes
por: Casey-Power, Saoirse, et al.
Publicado: (2022) -
Triamcinolone acetonide acetate
por: Lu, Xiao, et al.
Publicado: (2011) -
Glycyrrhizin could reduce ocular hypertension induced by triamcinolone acetonide in rabbits
por: Song, Zhengyu, et al.
Publicado: (2011)